Study details
Enrolling now
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
NCT IDNCT06699602ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
10
Study length
about 3 years
Ages
18+
Locations
7 sites in NJ, NY
What this study is about
This trial is testing whether giving cemiplimab and fianlimab before surgery for kidney cancer can be done safely and effectively. The researchers will also look at how this treatment affects tumor size before planned surgery.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Cemiplimab
- 2.Take Fianlimab
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
cemiplimab
Body systems
Oncology